Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q2 2024 ▲▼ | Q3 2024 ▲▼ | Change ▲▼ | Q2 2024 ▲▼ | Q3 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Arcellx, Inc. COMMON STOCK | 2,346,630 | 2,346,630 | 0 | $129.51M | $195.97M | 39.29% | +$66.46M |
| Zenas BioPharma, Inc.(ZBIO) | 0 | 4,911,539 | +4,911,539 | $0 | $83.10M | 16.66% | +$83.10M |
| ARS Pharmaceuticals, Inc.(SPRY) | 4,012,903 | 4,012,903 | 0 | $34.15M | $58.19M | 11.67% | +$24.04M |
| CRISPR Therapeutics AG(CRSP) | 1,048,951 | 1,048,951 | 0 | $56.65M | $49.28M | 9.88% | -$7.37M |
| Design Therapeutics, Inc.(DSGN) | 6,526,476 | 6,526,476 | 0 | $21.86M | $35.11M | 7.04% | +$13.25M |
| Mineralys Therapeutics, Inc.(MLYS) | 2,016,822 | 2,016,822 | 0 | $23.60M | $24.42M | 4.90% | +$826.9K |
| Alumis Inc. | 1,959,896 | 1,959,896 | 0 | $26.07M | $20.93M | 4.20% | -$5.13M |
| Nkarta, Inc.(NKTX) | 3,333,333 | 3,333,333 | 0 | $19.70M | $15.07M | 3.02% | -$4.63M |
| Oruka Therapeutics, Inc.(ORKA) | 0 | 375,330 | +375,330 | $0 | $9.20M | 1.84% | +$9.20M |
| enGene Holdings Inc. COM | 500,000 | 747,750 | +247,750 | $4.71M | $4.94M | 0.99% | +$220.2K |
| KALA BIO, Inc.(KALA) | 443,661 | 443,661 | 0 | $3.15M | $2.53M | 0.51% | -$616.7K |